miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.

Abstract

BACKGROUND:

Triple negative breast cancer (TNBC) lacks both early detection biomarkers and viable targeted therapeutics. Moreover, chemotherapy only produces 20-30% pathologic complete response. Because miRNAs are frequently dysregulated in breast cancer and have broad tissue effects, individual or combinations of circulating miRNAs may serve as ideal diagnostic, predictive or prognostic biomarkers, as well as therapeutic targets. Understanding the role and mechanism of dysregulated miRNAs in TNBC may help to develop novel diagnostic and prognostic strategy for TNBC patients.

METHODS:

The miRNA array profiles of 1299 breast cancer patients were collected from the Metabric database and subjected to analysis of the altered miRNAs between TNBC and non-TNBC. In Student's t-test and Kaplan-Meier analysis, four upregulated miRNAs correlated with poor survival in TNBC but not in non-TNBC. Four miRNAs were manipulated in multiple cell lines to investigate their functional role in carcinogenesis. From these results, we studied miR-105 and miR-93-3p in greater detail. The level of miR-105 and miR-93-3p were evaluated in 25 breast cancer tumor tissues. In addition, the diagnostic utility of circulating miR-105 and miR-93-3p were examined in 12 normal and 118 breast cancer plasma samples by ROC curve construction.

RESULTS:

miR-105 and miR-93-3p were upregulated and correlated with poor survival in TNBC patients. Both miR-105 and miR-93-3p were found to activate Wnt/β-catenin signaling by downregulation of SFPR1. By this action, stemness, chemoresistance, and metastasis were promoted. Importantly, the combination of circulating miR-105/93-3p may serve as a powerful biomarker for TNBC, even in early-stage disease.

CONCLUSIONS:

miR-105/93-3p activates Wnt/β-catenin signaling by downregulating SFRP1 and thereby promotes stemness, chemoresistance, and metastasis in TNBC cells. Most importantly, combined circulating miR-105/93-3p levels represent a prime candidate for development into a diagnostic biomarker for both early- and late-stage TNBC.

• Authors: Hao-Yi Li, Jui-Lin Liang, Yao-Lung Kuo, Hao-Hsien Lee, Marcus J Calkins, Hong-Tai Chang, Forn-Chia Lin, Yu-Chia Chen, Tai-I Hsu, Michael Hsiao, Luo-Ping Ger, Pei-Jung Lu
• Journal: Breast cancer research : BCR (Breast Cancer Res) Vol. 19 Issue 1 Pg. 133 (Dec 19 2017) ISSN: 1465-542X [Electronic] England
• PMID: 29258605 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• Circulating MicroRNA
• MIRN105 microRNA, human
• MIRN93 microRNA, human
• MicroRNAs

Topics

• Antineoplastic Agents (pharmacology)
• Biomarkers, Tumor
• Case-Control Studies
• Circulating MicroRNA
• Drug Resistance, Neoplasm (genetics)
• Female
• Humans
• Kaplan-Meier Estimate
• MicroRNAs (blood, genetics)
• Neoplasm Grading
• Neoplasm Metastasis
• Neoplasm Staging
• Prognosis
• ROC Curve
• Transcriptome
• Triple Negative Breast Neoplasms (diagnosis, drug therapy, genetics, mortality)
• Wnt Signaling Pathway